Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney

Ansari, Jawaher; Fatima, Arfeen; Chaudhri, S.; Bhatt, Rupesh I.; Wallace, M. Christopher; James, Nicholas D.

doi:10.1159/000183736

Cited by 27 publications

(20 citation statements)

References 12 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Miyake et al 37 reported a contribution of sunitinib to a slight decrease in metastatic tumour burden that fell short of a partial response. Finally, Ansari et al 38 reported a response, with minimal side effects, to sorafenib in a patient with metastatic cdc.…”

Section: 24mentioning

confidence: 97%

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

et al. 2013

View full text Add to dashboard Cite

Introduction: Collecting duct carcinoma (CDC) is a rare, aggressive form of renal carcinoma that presents at an advanced stage and has a poor prognosis. Little is known concerning the optimal management of CDC. We present the results of a systematic review addressing the management of CDC and the McMaster University CDC series. Methods: The MEDLINE, Cochrane Library, and EMBASE databases and conference proceedings were searched to identify studies relating to the management of CDC. Included studies reported on a minimum of 10 subjects receiving a single intervention. Series in which an evaluation of therapeutic effectiveness was not possible were excluded. The McMaster University (Hamilton, Ontario) series of 6 cases of CDC were retrospectively reviewed. Results: We identified 3 studies relevant to the management of CDC that included a total of 72 patients. A gemcitabine–cisplatin or –carboplatin regimen resulted in a 26% objective response rate in 23 patients with metastatic CDC. Two additional studies indicated that 49 patients treated with immunotherapy achieved no response. In the McMaster series, cytoreductive nephrectomy was performed in 4 of 6 patients. In 2 patients, MVAC therapy (methotrexate–vinblastine–doxorubicin–cisplatin) achieved no response. No significant therapeutic complications occurred, but survival was poor (median: 11 months; range: 10–33 months). Conclusions: Our review and clinical experience suggest that the current standard of care for metastatic CDC is a gemcitabine–cisplatin regimen.

show abstract

Section: 24mentioning

confidence: 97%

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Recently, the favorable clinical activity of sunitinib against non-clear cell carcinomas, including papillary and chromophobe carcinomas, has also been reported [8,9]; however, this is the first reported case demonstrating a therapeutic response of metastatic CDC to sunitinib. Furthermore, a recent report presented a case of metastatic CDC showing response to sorafenib [10]. Although the precise molecular mechanism involved in the antitumor activity of multiple tyrosine kinase inhibitors against CDC remains largely unknown, these findings suggest that the efficacy of these agents, for example sunitinib and sorafenib, against metastatic CDC needs to be prospectively evaluated.…”

Section: Discussionmentioning

confidence: 99%

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

et al. 2010

View full text Add to dashboard Cite

Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.

show abstract

“…Although radical surgery is the basic type of therapy and different protocols have been applied, the challenge involves the identification of novel therapeutic modalities (9). no standard protocols have been established for the treatment of CDC.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature

et al. 2010

View full text Add to dashboard Cite

Abstract. Collecting duct carcinoma (CDC) or Bellini duct carcinoma of the kidney is a rare, but highly aggressive renal epithelial malignancy, with an extremely poor prognosis. Modified cytokine-induced killer (mCIK) cells were injected into the pleural cavity to treat pleural metastasis of CDC. The patient, a 33-year-old male, was admitted to hospital for further treatment for severe pleural metastasis of CDC. We cured the pleural metastasis through intrapleural infusion with mCIK cells. After receiving this innovative treatment, the patient exhibited a positive response: the cough, dyspnea, chest distress and thoracalgia were evidently relieved, while the pleural fluid became clear after exhibiting haematodes and its level decreased significantly. The patient achieved partial success. This novel immunotherapy method is a promising treatment for patients with refractory pleural metastasis. IntroductionCollecting duct carcinoma (CDC) or Bellini duct carcinoma, which accounts for 1-3% of all renal neoplasms (1), is a rare variant of renal cell carcinoma (RCC) originating in the collecting duct epithelium and occurring more frequently in relatively young adults (2). Patients with CDC often require a more aggressive clinical course, have a poor long-term survival rate and, currently no standard treatment regimens exist (3). CDC and clear cell RCC typically present with a renal mass, macroscopic hematuria and associated flank pain. However, the majority of patients with CDC show evidence of metastatic disease at the time of presentation (3). Pleural metastasis of CDC is resistant to chemotherapy and radiotherapy, while immunotherapy, especially adoptive immune cell treatment, becomes a promising treatment for pleural metastasis. The present study evaluated a patient with pleural metastasis of CDC who achieved partial success following intrapleural infusion with modified cytokine-induced killer (mCIK) cells. Case reportA 33-year-old male with no significant past medical history was referred for urology review after a mass was found during a regular examination. A left radical nephrectomy was performed in December 2006 in the First Affiliated Hospital, Kunming Medical College, China. The pathology revealed CDC (Fig. 1) in the left kidney with no lymph node metastasis. After 1 year, the patient suffered from constant coughing, dyspnea, chest distress and thoracalgia. A chest X-Ray revealed a left pleural effusion. The pleural effusion recurred 1 month after B-ultrasound-guided therapeutic thoracentesis. For further treatment, the patient was referred to our institution on May 5th, 2008.A physical examination revealed a dull sound on percussion and the breath sounds disappeared below the sixth left rib. A computed tomography (CT) scan of the chest, abdomen and pelvis revealed no local recurrence and no lymph node metastasis, although severe pleural metastasis was noted. The examination results revealed that the left pleural had thickened, the pleural effusion was partly encapsulated and there was left pulmonary atelect...

show abstract

Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney

Cited by 27 publications

References 12 publications

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature

Contact Info

Product

Resources

About